Recent research in mice suggests that semaglutide, the drug found in Ozempic and Wegovy, could offer significant benefits for longevity and aging. A study published by researchers from UC Berkeley found that mice treated with semaglutide lived approximately 100 days longer than their counterparts who did not receive the drug, marking a 12% increase in lifespan.
Researchers observed improvements in the treated mice across various biological markers, including blood composition, appearance, and behavior. The study suggests that semaglutide may impact multiple biological changes associated with aging, often referred to as the "hallmarks of aging." These hallmarks include chronic inflammation, DNA damage accumulation, cellular senescence, and mitochondrial dysfunction.
According to Danica Chen, a professor of metabolic biology and nutrition at UC Berkeley and an author of the study, the findings could potentially expand the use of GLP-1 medicines to healthy individuals seeking to extend their lifespan and healthspan. The research indicates that the drug's effects might go beyond simple calorie restriction, which is known to extend life.
Comparison to Calorie Restriction
In a separate experiment, researchers compared mice on semaglutide to mice that were subjected to calorie restriction alone. While both groups exhibited similar results in weight and fat loss, physical activity, coordination, muscle function, and exercise capacity, the mice treated with semaglutide showed distinct advantages. These included a greater willingness to explore their environment, improved performance in spatial memory tests (like navigating a maze), and better blood sugar regulation. Chen noted that these differences suggest GLP-1 drugs may activate biological pathways independent of calorie restriction.
Previous research has indicated that GLP-1s can help slow cognitive decline in humans with type 2 diabetes. The current study's findings on memory performance in mice could translate to potential cognitive benefits for aging humans. Additionally, the study's findings on improved blood sugar regulation may offer a pathway to managing age-related metabolic issues, such as insulin resistance and type 2 diabetes, which are linked to cardiovascular and cerebrovascular risks.
Implications for Chronic Disease
Rafael de Cabo, a senior investigator at the National Institute on Aging (NIA) and an author of a commentary on the study, stated that if GLP-1 agonists effectively slow the aging process, a wide range of clinical benefits would be expected. Aging is a primary risk factor for numerous chronic conditions, including cancer, Alzheimer's disease, heart disease, and diabetes. The study's results suggest that semaglutide could potentially play a role in mitigating these age-related diseases. However, the authors emphasized that further research is necessary to confirm these effects in humans.